Follow-on products for treatment of multiple sclerosis in Latin America: An update

Correale, Jorge

doi:10.1016/j.jns.2017.08.3242

Cited by 3 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, PwMS frequently face significant difficulties as a result of replacement of official innovator DMT, by generic or biosimilar compounds. 19,25 This was the case in Argentina, where 68% of PwMS surveyed had originally been prescribed innovator DMT, but reported these had been replaced by generic or biosimilar drugs, a very different scenario from that of other LATAM countries (Chile, Colombia, Honduras, and Mexico (⩽1%)). DMTs are frequently switched by HI companies during the course of treatment, for different compounds with the same active ingredient but of another trademark.…”

Section: Discussionmentioning

confidence: 99%

Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients

2020

Self Cite

View full text Add to dashboard Cite

Background: Multiple sclerosis (MS), is an emergent disease in Latin America (LATAM), which raises substantial socioeconomic challenges to a region where most countries remain as economies in development. Objective: To assess barriers to access and utilization of MS care services in a regional cohort survey. Methods: We conducted a cross-sectional study based on a self-reported survey. Patients with MS (PwMS) completed this regional survey in 12 Latin American (LATAM) countries. PwMS were also divided into those with healthcare insurance (including certain local national social security programs) and those without healthcare insurance (treated at public institutions). Results: We surveyed 1469 PwMS and identified significant regional differences in relation to access to complementary tests, rehabilitation services, and prescription of disease-modifying therapies (DMTs). Between 44.4% and 73.5% of PwMS were unemployed and nearly 50% had completed higher education. PwMS receiving care from the private sector reported greater access to imaging, DMTs, and fewer problems obtaining DMTs compared to those treated at public institutions. Multivariate analysis showed that lack of private insurance (OR = 2.21, p < 0.001), longer MS duration (OR = 1.02, p = 0.001), lower level of education (OR = 0.66, p = 0.009), and unemployment (OR = 0.73, p = 0.03) were independently associated with inappropriate delivery of DMTs. Conclusion: These findings suggest barriers to access and utilization of MS care services across LATAM are prevalent. We identified several factors predicting unmet healthcare needs in PwMS.

show abstract

Section: Discussionmentioning

confidence: 99%

Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients

2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…If cladribine is used, suspension is recommended 6 months before conception, both for men and women. In the case of ocrelizumab, women are advised to wait 6 months after the last dose to attempt pregnancy (7)(8)(9)(10)(11)(12)(13)(14).…”

Section: F Approach To Patients Wishing To Become Pregnant or Breastmentioning

confidence: 99%

Central American and Caribbean Consensus for the Treatment of Multiple Sclerosis and Therapeutic Attitudes Facing the COVID-19 Pandemic

Díaz¹,

Gracia

Monterrey-Alvarez

et al. 2020

J Current Med Res Opinion

View full text Add to dashboard Cite

Therapeutic decisions for multiple sclerosis have become more complex in the Central American and Caribbean region (CAC), with new treatments appearing every year but with well-known limitations in terms of access and application. Concomitantly, the advent of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, with an increasing number of cases in the region, has increased the need for a consensus on therapeutic decisions to be made for people with multiple sclerosis. Under these circumstances, a reference framework is needed to gather current information to assist neurologists in making therapeutic decisions. An evidence-based consensus on the use of disease-modifying therapies for multiple sclerosis was proposed and accomplished by the Central American and Caribbean Multiple Sclerosis Forum (FOCEM), including recommendations for treatment during the pandemic. Using the consensus panel development methodology, after a bibliographic review of the best quality and actualized information, a final report was written; this includes statements that reached more than 70% consensus among the panel of experts. The recommendations encompass indications for drugs available for multiple sclerosis, definitions of therapeutic failure, patient follow-up, factors of poor prognosis, discontinuation of treatment, treatment during pregnancy and lactation and specific recommendations to apply during the SARS-CoV-2 pandemic.

show abstract

Consensus recommendations on the management of multiple sclerosis patients in Argentina

Cristiano

Rojas

Alonso

et al. 2020

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Follow-on products for treatment of multiple sclerosis in Latin America: An update

Cited by 3 publications

References 35 publications

Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients

Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients

Central American and Caribbean Consensus for the Treatment of Multiple Sclerosis and Therapeutic Attitudes Facing the COVID-19 Pandemic

Consensus recommendations on the management of multiple sclerosis patients in Argentina

Contact Info

Product

Resources

About